Memokath
Commercial- Indications
- Urinary tract obstruction, Prostatic obstruction, Ureteric stricture, Bladder neck stricture
Company intelligence / Profile preview
Memokath™ stents are commercially available and have been clinically validated. The Memokath™051 Ureter was the first metallic stent recommended by NICE in the UK after extensive clinical testing. The company’s products are used globally and have a strong presence in Europe and Asia. Memocore™, a metallic fiducial marker for radiation therapy, has also been launched following R&D with Aalborg University Hospital. No ongoing clinical trials or investigational-stage programs are mentioned; all key products appear to be on market.
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Pnn Medical.